ReviewFrontiers in immunology2018
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 239 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
239 citing papers in PubMed, 2 syntheses or guidelines pooled it, 448 citations in OpenAlex.
- Circulating inflammatory cytokines and psoriasis risk: A systematic review and meta-analysis.PloS one · 2023Pooled it
- A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa.European psychiatry : the journal of the Association of European Psychiatrists · 2021Pooled it
- Impact of treatment interruption on the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis: aFrontiers in immunology · 2025Trial
- A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product CosentyxDrug design, development and therapy · 2024Trial
- Impact of topical emollient, steroids alone or combined with calcipotriol, on the immune infiltrate and clinical outcome in psoriasis.Experimental dermatology · 2022Trial
- Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.Annals of the rheumatic diseases · 2021Trial
- Impact of Hormonal Contraceptives on Cervical T-helper 17 Phenotype and Function in Adolescents: Results from a Randomized, Crossover Study Comparing Long-acting Injectable Norethisterone Oenanthate (NET-EN), Combined Oral Contraceptive Pills, and Combined Contraceptive Vaginal Rings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis).Dermatology and therapy · 2026Article
- Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A C-Nucleoside Analogue of Cordycepin With High Metabolic Stability and Potent Anti-Psoriatic Activity via Microneedle Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- DYRK kinases phosphorylate IL-17RA at S801.Serican journal of medicine · 2026Article
- An Overview and Trend Analysis of Biosimilar Approvals in China.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- APOA1, DEFB103A_DEFB103B and DSG3 Are Novel Circulating Biomarkers of Psoriasis.International journal of molecular sciences · 2026Article
- Synthesis, Biological Evaluation and Structure-Activity Relationship of Juglone Derived Naphthoquinones as Potential Antipsoriatic Agents.Biomolecules · 2026Article
- Integrating network pharmacology, transcriptomics, and experimental validation: Compound Baixianpi Formula targets IL-17A to inhibit dual PI3K-AKT/JAK2-STAT3 pathways for psoriasis improvement.Chinese medicine · 2026Article
- MPGK: A user-friendly tool for Mendelian randomization, polygenic risk score, Geno Ontology, and the Kyoto Encyclopedia of Genes and Genomes analysis.Chinese medical journal · 2026Article
- Interleukin-17 in Health and Disease: Special Focus on Its Role in Autoimmune Hepatitis.Cells · 2026Review
- Mechanistic insights into the neuroprotective effects of yangyin formula on cerebral ischemia-reperfusion injury via the IL-17A/MAPK/NF-κB signaling pathway.Journal of molecular histology · 2026Article
- Olive (Olea europaea) phenolics for the control of psoriasis via targeting SMYD2 and IL-17A protein-protein interaction networks.Journal of natural medicines · 2026Article
179 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a frequent chronic inflammatory skin disease, nowadays considered a major global health problem. Several new drugs, targeting the IL-23/IL-17A pathway, have been recently licensed or are in clinical development. These therapies represent a major improvement of the way in which psoriasis is managed, since they show an unprecedented efficacy on skin symptoms of psoriasis. This has been made possible, thanks to an increasingly more accurate pathogenic view of psoriasis. Today, the belief that Th17 cells mediate psoriasis is moving to the concept of psoriasis as an IL-17A-driven disease. New questions arise at the horizon, given that IL-17A is part of a newly described family of cytokines, which has five distinct homologous: IL-17B, IL-17C, IL-17D, IL-17E, also known as IL-25 and IL-17F. IL-17 family cytokines elicit similar effects in target cells, but simultaneously trigger different and sometimes opposite functions in a tissue-specific manner. This is complicated by the fact that IL-17 cytokines show a high capacity of synergisms with other inflammatory stimuli. In this review, we will summarize the current knowledge around the cytokines belonging to the IL-17 family in relation to skin inflammation in general and psoriasis in particular, and discuss possible clinical implications. A comprehensive understanding of the different roles played by the IL-17 cytokines is crucial to appreciate current and developing therapies and to allow an effective pathogenesis- and mechanisms-driven drug design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.